SG10201810496XA - Nmda receptor modulators and prodrugs, salts, and uses thereof - Google Patents

Nmda receptor modulators and prodrugs, salts, and uses thereof

Info

Publication number
SG10201810496XA
SG10201810496XA SG10201810496XA SG10201810496XA SG10201810496XA SG 10201810496X A SG10201810496X A SG 10201810496XA SG 10201810496X A SG10201810496X A SG 10201810496XA SG 10201810496X A SG10201810496X A SG 10201810496XA SG 10201810496X A SG10201810496X A SG 10201810496XA
Authority
SG
Singapore
Prior art keywords
prodrugs
salts
compounds
nmda receptor
receptor modulators
Prior art date
Application number
SG10201810496XA
Inventor
M Amin Khan
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of SG10201810496XA publication Critical patent/SG10201810496XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. Fig. 1
SG10201810496XA 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof SG10201810496XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361896308P 2013-10-28 2013-10-28

Publications (1)

Publication Number Publication Date
SG10201810496XA true SG10201810496XA (en) 2018-12-28

Family

ID=53004986

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201810496XA SG10201810496XA (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof
SG11201603376UA SG11201603376UA (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201603376UA SG11201603376UA (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof

Country Status (15)

Country Link
US (2) US9745342B2 (en)
EP (2) EP3564256A1 (en)
JP (1) JP6603668B2 (en)
KR (1) KR20160077153A (en)
CN (2) CN112321678A (en)
AU (2) AU2014342624A1 (en)
BR (1) BR112016009443A8 (en)
CA (1) CA2928701A1 (en)
CL (2) CL2016001001A1 (en)
IL (1) IL245302B (en)
MX (2) MX2016005510A (en)
RU (1) RU2016119830A (en)
SA (1) SA516371037B1 (en)
SG (2) SG10201810496XA (en)
WO (1) WO2015065891A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073108A (en) 2013-01-22 2015-11-18 维斯塔津治疗公司 Dosage forms and therapeutic uses of l-4-chlorokynurenine
CN116082461B (en) * 2022-10-14 2023-11-14 浙江大学 Small molecular peptide with antibacterial activity and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090263858A1 (en) 2004-09-14 2009-10-22 Shionogi & Co., Ltd. Process for synthesis of mucin-type peptides and muc1-related glycopeptides
AU2007333846B2 (en) * 2006-12-14 2014-01-23 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
WO2008104000A2 (en) * 2007-02-23 2008-08-28 Aileron Therapeutics, Inc. Triazole macrocycle systems
RU2515615C2 (en) * 2008-09-18 2014-05-20 Нортвестерн Юниверсити Nmda receptor modulators and using them
JP2012503025A (en) * 2008-09-22 2012-02-02 エルロン・セラピューティクス・インコーポレイテッド Method for preparing a purified polypeptide composition
KR101692275B1 (en) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
MX2012009388A (en) * 2010-02-11 2012-10-01 Univ Northwestern Secondary structure stabilized nmda receptor modulators and uses thereof.
CA2834286A1 (en) * 2011-04-27 2012-11-01 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders

Also Published As

Publication number Publication date
US20160244485A1 (en) 2016-08-25
KR20160077153A (en) 2016-07-01
EP3564256A1 (en) 2019-11-06
IL245302A0 (en) 2016-06-30
US20180127466A1 (en) 2018-05-10
IL245302B (en) 2020-05-31
SG11201603376UA (en) 2016-05-30
RU2016119830A3 (en) 2018-07-02
JP2016537413A (en) 2016-12-01
EP3062810A1 (en) 2016-09-07
CA2928701A1 (en) 2015-05-07
AU2014342624A1 (en) 2016-06-02
SA516371037B1 (en) 2018-05-16
AU2020201109A1 (en) 2020-03-05
US9745342B2 (en) 2017-08-29
CL2016001001A1 (en) 2016-12-16
BR112016009443A8 (en) 2020-03-24
EP3062810A4 (en) 2017-05-03
JP6603668B2 (en) 2019-11-06
US10590167B2 (en) 2020-03-17
MX2016005510A (en) 2017-01-06
CN112321678A (en) 2021-02-05
WO2015065891A1 (en) 2015-05-07
CL2020002247A1 (en) 2021-02-05
CN105764522A (en) 2016-07-13
MX2021000029A (en) 2021-03-25
RU2016119830A (en) 2017-12-04

Similar Documents

Publication Publication Date Title
PH12015501601B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501596A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2013063120A3 (en) Nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP2542254A4 (en) Secondary structure stabilized nmda receptor modulators and uses thereof
GEP20207082B (en) Prodrugs of pyridone amides useful as modulators of sodium channels
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019001322A (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX2015016983A (en) Nuclear transport modulators and uses thereof.
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
UA118474C2 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
UA109793C2 (en) Arylsulphonamide derivatives for the treatment of disorders of the central nervous system
MX2021000029A (en) Nmda receptor modulators and prodrugs, salts, and uses thereof.
MX2015009414A (en) Topical ocular analgesic agents.
MX368641B (en) Compounds for treating inflammation and pain.